Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sowmya Saiganesh"'
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Kristin Lewis Wilson, Harbani K. Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Rodolfovan D. Yabut, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy t
Externí odkaz:
https://doaj.org/article/9e96f15bb0a54d7bb137adf3be604c3c
Autor:
Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein, Hannes Kehm, Aarti Balasubramani, Andrew A. Boudreau, Ben Buelow, Karen Chang, Laura M. Davison, Suhasini Iyer, Vidyut Kalwit, Harbani Malik-Chaudhry, Will Pierson, Geovanni Pineda, Udaya S. Rangaswamy, Sowmya Saiganesh, Ute Schellenberger, Harshad S. Ugamraj, Roland Buelow, Jocelyn Chapman, Nathan D. Trinklein, Katherine E. Harris
Publikováno v:
Cancer Research. 82:6244-6244
The use of T cell engagers (TCEs) to treat solid tumors in humans is challenging, and several have been limited by narrow therapeutic windows due to substantial toxicity. Dose-limiting toxicities of TCEs include cytokine release syndrome (CRS) and on
Autor:
Aarti Balasubramani, Ute Schellenberger, Harshad Ugamraj, Suhasini Iyer, Nathan D. Trinklein, Laura Davison, Brian Avanzino, Sharon Hartstein, Ben Buelow, Andrew Boudreau, Sowmya Saiganesh, Priya Ganesan, Duy Pham, Udaya Rangaswamy, Kirthana Prabhakar, Hannes Kehm, Harbani K. Malik-Chaudhry, Katherine E. Harris
Publikováno v:
Journal of Clinical Oncology. 38:e18050-e18050
e18050 Background: Ovarian Cancer (OvCa) is the leading cause of gynecologic cancer mortality in women. Since the introduction of platinum-based chemotherapy there has been little change in the prognosis of OvCa patients, with < 30% overall survival